Cell Death Dis: Brown University study, drug treatments can improve the effectiveness of cancer immunotherapy

!----: Immunotherapy is a treatment that uses the body's own immune system to identify, attack, and kill tumor cells, and while it has given hope to people around the world, it has failed in many cancer patients, researchers at Brown University in the United States have found that blocking the tumor-promoting protein MDM2 can enhance the effectiveness of immunotherapyImmunotherapytumors is designed to activate the body's immune system and rely on autoimmune function to kill cancer cells and tumor tissuethis revolutionized traditional cancer treatments and had a significant response to a variety of previously incurable tumorsHowever, resistance from patients receiving immunotherapy remains a major challengein addition to primary drug resistance, another challenge is the phenomenon of over-progression of the disease (HPD), which accelerates tumor growth in patients receiving immunotherapy, researchers at Brown University in the United States recently found that blocking the tumor-promoting protein MDM2 can increase the efficacy of immunotherapythe study, led by DrWafik El-Deiry, associate dean of oncology at Brown University and professor of pathology and experimental medicine, and published online in the journal Cell Death Discovery"Immune therapy is one of the biggest breakthroughs in biomedical and medical science over the past 20 years, but it has its limitations," said Professor El-Deiry,the title "AMG-232 sensitizes high MDM2-expressing tumor cells to T-cell-mediad""Some patients' tumors initially respond to immunotherapy and then recur."and some patients experience false progression, i.ethe tumor begins to grow again before it shrinkssome patients (5 to 29 per cent of all patients) experience progression, which means that immunotherapy actually makes their tumor growth worsemany previous studies have found that when the MDM2 gene is amplified (which means that cells contain too many copies of the gene), or when MDM2 proteins are expressed due to poor gene regulation, tumor cells tend to grow faster and become more resistant to immunotherapy researchers are still studying why this accelerated growth and resistance occurs, but studies have shown that MDM2 can help tumors grow and evade the immune system through a variety of mechanisms , for example, MDM2 appears to inactivate the tumor suppressor gene p53 and prevents immune cells from killing tumor cells, and it is also associated with elevated levels of an inflammatory protein calledininiin 6 (IL-6) high expression of MDM2 helps with immune escape, El-Deiry hopes to block MDM2 by genetically silencing or suppressing MDM2 drug AMG-232 to enhance the role of immunotherapy in the study, they used AMG-232 to treat the overexpression of the ovarian cancer cell line with MDM2 experimental data show that AMG-232 can make immune cells more effective in killing tumor cells and lower IL-6 levels these results suggest that MDM2 inhibitors can be combined with immunotherapy to improve their efficacy targeting MDM2 with AMG-232 to make MDM2-expressing high-expression tumor cells sensitive to The Killing of T-cell-mediated, El-Deiry hopes the study will lead to clinical trials so that the team can further evaluate the safety and effectiveness of the new treatment Because MDM2 amplification and overexpression are associated with a variety of cancers, he believes that AMG-232 (or similar drugs, including drugs that block MDM2 and related protein MDMX) can be widely used and even benefit patients with normal levels of MDM2 "We think this may be a good way to treat patients with over-advanced tumors, but I would say that our results show that even if MDM2 is not amplification or overexpression, targeted MDM2 combination immunotherapy works well," said El-Deiry, it takes advantage of the internal vulnerability of the tumor to help immunotherapy work better " the study followed the establishment of the Brown University Cancer Center, where El-Deiry was the center's first director the center builds on Brown University's growing emphasis on the practice of translational science, from an effort to understand how cancer develops, grows and metastasis to develop new treatments for patients in a personalized way to meet their needs from risk to survival